MedTrace Logo

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

NCT01154634 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-08-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.

Conditions

  • Reflux

Interventions

DRUG

AZD2516, 5 mg

Capsule, oral

DRUG

AZD2516, 16 mg

Capsule, oral

DRUG

AZD2516, 40 mg

Capsule, oral

DRUG

Placebo

Capsule, oral

Sponsors & Collaborators

Principal Investigators

  • Mark Berner Hansen · AstraZeneca R&D Molndal

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01154634 on ClinicalTrials.gov